[go: up one dir, main page]

WO2023283699A1 - Appareil et procédé de photobiomodulation - Google Patents

Appareil et procédé de photobiomodulation Download PDF

Info

Publication number
WO2023283699A1
WO2023283699A1 PCT/AU2022/050750 AU2022050750W WO2023283699A1 WO 2023283699 A1 WO2023283699 A1 WO 2023283699A1 AU 2022050750 W AU2022050750 W AU 2022050750W WO 2023283699 A1 WO2023283699 A1 WO 2023283699A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment unit
light
user
light sources
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2022/050750
Other languages
English (en)
Inventor
Michael Whitmore
Sheila Thompson
Jaydee WILK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Twobeseen Pty Ltd
Original Assignee
Twobeseen Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021902200A external-priority patent/AU2021902200A0/en
Application filed by Twobeseen Pty Ltd filed Critical Twobeseen Pty Ltd
Publication of WO2023283699A1 publication Critical patent/WO2023283699A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0616—Skin treatment other than tanning
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0626—Monitoring, verifying, controlling systems and methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
    • A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
    • A61N2005/0645—Applicators worn by the patient
    • A61N2005/0647—Applicators worn by the patient the applicator adapted to be worn on the head
    • A61N2005/0648—Applicators worn by the patient the applicator adapted to be worn on the head the light being directed to the eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/065—Light sources therefor
    • A61N2005/0651—Diodes
    • A61N2005/0652—Arrays of diodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light

Definitions

  • the present disclosure relates to photobiomodulation apparatus and methods for treating the human or animal eye and its surrounding tissues using light therapy.
  • Some disclosed embodiments relate to a wearable apparatus for providing and directing light onto treatment areas of a user’s face, particularly the user’s eyes and surrounding tissues.
  • Skin aging and/or inflammation may be caused or exacerbated by exposure to irritants, pollutants, chemical agents, or other environmental factors.
  • Exposure to ultraviolet (UV) light and radiation may accelerate the natural aging process, and lead to undesirable outcomes such as skin damage, rhytides, and wrinkling.
  • Exposure to UV light breaks down the skin’s connective tissue, collagen, and elastin fibres, which lie in the deeper layer of skin (dermis). Without this supportive connective tissue, the skin loses strength and flexibility, and begins to sag, form rhytides, and wrinkle.
  • the breakdown of the skin’s connective tissue may lead to a loss of support for other organs and systems such as the circulatory and lymphatic systems. This can lead to a loss of normal organ function causing conditions such as inflammation or poor immune response.
  • the eyes are particularly vulnerable to UV light damage as the light penetrates all the way to the retina. Conditions such as cataracts and macular degeneration are often a result of over exposure to UV.
  • Dry eye disease is a multifactorial disease of the tears and ocular surface that causes tear film instability with potential damage to the ocular surface. It is thought that the prevalence of dry eye disease in the world population ranges from 6% to 34%. Dry eye disease is typically more common in those aged over 50, and twice as common in women. Furthermore, it is also understood that a younger population is being impacted by dry eye symptoms, which is considered likely to be related to increasing exposure to and use of digital devices and the associated blue light emissions.
  • Photobiomodulation also known as low level light therapy (LLLT) is a treatment in which a patient (human or animal) is exposed to low-level light, such as via laser or light emitting diode. Photobiomodulation can stimulate cellular function leading to beneficial clinical effects.
  • LLLT low level light therapy
  • an appropriate combination of wavelength, intensity, duration, and treatment interval is complex with different diseases, injuries and dysfunctions needing different treatment parameters and techniques.
  • Some embodiments relate to an apparatus for delivery of photobiomodulation (PBM) therapy, the apparatus comprising: a treatment unit, the treatment unit defining an inner surface and an outer surface, wherein the treatment unit is configured to be worn by a user such that the inner surface of the treatment unit faces an eye area of the user; an array of light sources coupled to the inner surface of the treatment unit, the array configured to emit light waves from the inner surface of the treatment unit; a controller operably connected to the array and configured to control emission of the light waves; wherein each one of the light sources in the array is configured to emit the light waves outwardly from the inner surface of the treatment unit to provide photodynamic stimulation of tissue spanned by the inner surface.
  • PBM photobiomodulation
  • the tissue spanned by the inner surface may comprise at least one of:
  • the treatment unit may additionally cover a nose region of the user. Further to the aforementioned tissue areas, the treatment unit may additionally cover a cheek region of the user. Further to the aforementioned tissue areas, the treatment unit may additionally cover both the nose region and the cheek region of the user.
  • At least one of the light sources may be configured to transmit light at a first wavelength, and at least another of the light sources may be configured to transmit light at a second wavelength different from the first wavelength.
  • the treatment unit may be configured to house the array of light sources and the controller.
  • the treatment unit may comprise a multi-layer arrangement, comprising an outer shell, a second layer, and a third layer.
  • the second layer may consist of the controller, a battery, a power source, and the array of light sources.
  • the outer shell may define a recess for receiving the second layer therein.
  • the third layer may have light diffusing qualities.
  • the apparatus may further comprise a frame configured to secure the apparatus to the face of the user, and the treatment unit may be removably attached to the frame.
  • the light sources may be LEDs connected to a circuit board housed within the treatment unit.
  • At least one of the light sources may emit light having a wavelength in the range of 629 nm to 700 nm. At least one of the light sources may emits light having a wavelength of 670 nm +/- 10 nm. At least one of the light sources may emit light having a wavelength of 799 nm to 860 nm. At least one of the light sources may emit light having a wavelength of 830 nm +/- 10 nm.
  • Some embodiments relate to a method for improving the functionality of the tissue of and around the eyes comprising: applying light with a predetermined set of photobiomodulating parameters to the eyes and surrounding areas tissues from a treatment apparatus; wherein the light has one or more wavelengths ranging from 630 nm +/- lOnm to 900 nm +/- 10 nm.
  • a target irradiance delivered by the apparatus may be 0.5 - 50 mW / cm2.
  • a target treatment time period may be between 1 and 30 minutes.
  • a target total delivered energy density may be between 0.1 and 25 J / cm2.
  • the target total delivered energy density may be between 0.1 and 5 J / cm2.
  • the apparatus used in the method may be the apparatus as defined above.
  • FIG. 1A is a first perspective view of an apparatus for delivering photobiomodulation therapy to the eye and surrounding areas, according to some embodiments;
  • Fig. IB is a second perspective view of an apparatus for delivering photobiomodulation therapy to the eye and surrounding areas, according to some embodiments;
  • Fig. 2A shows the exterior portion of the apparatus of Fig. IB, as viewed from the front of the apparatus;
  • FIG. 2B shows the interior portion of the apparatus of Fig. 2A, as viewed from the rear of the apparatus;
  • Fig. 2C is a section view of the apparatus of Fig. 2B, as taken along the line marked “Fig. 2C” therein, and showing the interior portion of the right hand side of the apparatus;
  • FIG. 3A shows the exterior portion of the apparatus of Fig. IB, as viewed from the right hand side of the apparatus;
  • FIG. 3B shows the exterior portion of the apparatus of Fig. IB, as viewed from the left hand side of the apparatus;
  • FIG. 4A is a top view of the apparatus of Fig. IB;
  • Fig. 4B is a bottom view of the apparatus of Fig. IB;
  • FIG. 4C is an exploded view of the apparatus of Fig. IB;
  • FIG. 5A shows an embodiment of the apparatus of Figs. 1A and IB, as worn by a user and as viewed from the front and left side of the apparatus;
  • Fig. 5B shows an outline of the apparatus of Fig. 5A, as viewed from the front and left side of the apparatus, to demonstrate positioning of the apparatus relative to the user’s face;
  • FIG. 6 is a simplified illustration of the areas of the user’s face and head to which embodiments of the apparatus are configured to deliver photobiomodulation light therapy;
  • Fig. 7A is a front view of the apparatus for delivering photobiomodulation therapy to the eye and surrounding areas, according to a further embodiment and shown as worn by a user;
  • Fig. 7B is a left hand side view of the apparatus of Fig. 7A.
  • Fig. 7C is a perspective view of the apparatus of Fig. 7A;
  • Fig. 8A shows the exterior portion of the apparatus of Fig. 7A, as viewed from the front of the apparatus;
  • Fig. 8B shows the interior portion of the apparatus of Fig. 7A, as viewed from the rear of the apparatus;
  • Fig. 9A shows the exterior portion of the apparatus of Fig. 7A, as viewed from the right hand side of the apparatus;
  • Fig. 9B shows the exterior portion of the apparatus of Fig. 7A, as viewed from the left hand side of the apparatus;
  • Fig. 10A is a top view of the apparatus of Fig. 7A;
  • Fig. 10B is a bottom view of the apparatus of Fig. 7A;
  • Fig. IOC is an exploded view of the apparatus of Fig. 7A;
  • the present disclosure relates to photobiomodulation apparatus and methods for treating the human or animal eye and its surrounding tissues using light therapy. Some disclosed embodiments relate to a wearable apparatus for providing and directing light onto treatment areas of a user’s face, particularly the user’s eyes and surrounding tissues. [0050] The present disclosure relates to a wearable, hands-free apparatus that is configured to deliver photobiomodulation therapy in the form of multi wavelength, low level light therapy, directly over the eyes and surrounding tissues. Disclosed embodiments generally relate to a photobiomodulation apparatus for promoting the health and appearance of the eye and surrounding areas.
  • Some embodiments of the apparatus provide photobiomodulation therapy across an area of the user’s face which may span from the temporal area, over the eyebrow / glabella region, below the tear trough across the nose and the midsection of the face, spanning to the pre auricular area on both sides. Some embodiments of the apparatus provide photobiomodulation therapy across the aforementioned areas of the user’s face, and may exclude the nose area.
  • the apparatus comprises a photobiomodulation therapy light source, which may comprise a plurality of light emitting diodes (LED) and/or organic light emitting diodes (OLED) and circuitry.
  • the present disclosure includes methods directed to promoting healing, reducing inflammation, redness, alleviating symptoms of dry eye and/or reducing the appearance of skin aging surrounding the eyes of a subject.
  • the methods involve application of red and near-infrared light therapy to the eye and the surrounding areas.
  • the disclosed methods may use embodiments of the disclosed apparatus.
  • Some embodiments of the apparatus are designed to deliver red and near infrared light therapy via light emitting diodes in photobiomodulating doses to the eye, including eyelids and/or the surrounding areas of the eye.
  • Red and near infrared light therapy is known to contribute to the improvement of cellular function through a reduction of oxidative stress, promoting ATP production, activating fibroblasts and stimulating collagen, encouraging tear breakdown, improving skin elasticity and tone, alleviating symptoms of dry eye, promoting healing and lymphatic drainage, reducing inflammation and redness in treated areas thereby promoting eye health, function, and appearance of treated areas.
  • the skin is made up of three layers, the Epidermis, the Dermis, and the Hypodermis (sometimes referred to as the subcutaneous layer). Within these layers we find the vascular system, the lymphatic system, the peripheral nerve system, sweat glands, sebaceous glands, and other miscellaneous tissues and structures. All these tissues are positively affected by photobiomodulation therapy with red and near infrared light.
  • the human eyelids are thin, mobile folds that cover the eyeball anteriorly.
  • the eyelids offer protection from excessive light or injury and maintain lubrication by distributing tears over the entire surface of the eyeball.
  • the eyelids are split into upper and lower portions, which meet at the medial and lateral canthi of the eye.
  • the opening between the two eyelids is called the palpebral aperture or opening.
  • the eyelid consists of five main layers (superficial to deep): skin and subcutaneous tissue, orbicularis oculi, tarsal plates, levitator apparatus, conjunctiva.
  • the skin and subcutaneous tissue form the most superficial layer of the eyelid. This layer of skin is amongst the thinnest in the human body. In the subcutaneous layer, there is loose connective tissue but no subcutaneous fat. As a result, the eyelids are easily distended by oedema or blood.
  • the orbicularis oculi muscle has three distinct parts - palpebral, lacrimal, and orbital.
  • the palpebral part gently closes the eyelids
  • the lacrimal part is involved in the drainage of tears
  • the orbital part tightly closes the eyelids. All of these parts are innervated via the facial nerve (temporal and zygomatic branches).
  • the tarsal plates are located deep to the palpebral region of the orbicularis oculi muscle. There are two plates: the superior tarsus (upper eyelid) and inferior tarsus (lower eyelid). They act to form the scaffolding of the eyelid and are composed of dense connective tissue. The superior tarsus also acts as the attachment site of the levator palpebrae superioris.
  • tarsal plates lie the Meibomian glands, these are a specialized type of sebaceous gland that secretes an oily substance onto the eye to slow the evaporation of the eye’s tear film. The oily substance also prevents the eyelid from sticking together when closed.
  • the levator palpebrae superioris and superior tarsal muscles both act to open the eyelid and they are both located in the upper eyelid.
  • the palpebral conjunctiva forms the deepest layer of the eyelid, it is a thin mucous membrane which covers the inside of the eyelid.
  • the eyelid has a rich arterial supply from numerous vessels including the Ophthalmic artery (lacrimal, medial palpebral, supraorbital, dorsal nasal and supratrochlear), the angular branch of the facial artery, and the transverse facial branch of the superficial temporal artery.
  • Venous drainage is provided by a rich network around the eyelid.
  • blood drains via the medial palpebral vein into the angular and ophthalmic veins.
  • blood drains into the superficial temporal vein from the lateral palpebral vein.
  • Sensory innervation to the eyelids is supplied by branches of the trigeminal nerve.
  • the Ophthalmic nerve is connected to the upper eyelid via the supraorbital, supratrochlear, infratrochlear, and lacrimal branches.
  • the Maxillary nerve is connected to the lower eyelid via the infraorbital and zygomaticofacial branches. Innervation to the muscles of the eyelid is via the facial nerve (orbicularis oculi), oculomotor nerve (levator palpebrae superioris) and sympathetic fibres (superior tarsal muscle).
  • UV light ultraviolet light and other stressors.
  • UV light which speeds the natural aging process, is considered the primary cause of rhytides and wrinkling.
  • Exposure to UV light breaks down the skin’s connective tissue, collagen, and elastin fibres, which lie in the deeper layer of skin (dermis). Without this supportive connective tissue, the skin tends to lose strength and flexibility, and may begin to sag, form rhytides, and wrinkle. Additionally, the breakdown of the skin’s connective tissue may lead to a loss of support for other organs and systems, such as the circulatory and lymphatic systems. In the case of the eyelids and surrounding areas, this breakdown may be particularly impactful due to the thinness of the skin and the critical eye functionality that it supports.
  • FIGs. 1A and IB are simplified schematic illustrations of embodiments of an apparatus 1 configured to deliver photobiomodulation therapy to the eye and/or the surrounding areas of the eye.
  • the apparatus 1 delivers photobiomodulation therapy by positioning a light source in fixed relation to the user’s face.
  • the apparatus 1 comprises a treatment unit 2.
  • the treatment unit 2 covers the user’s eyes when the apparatus 1 is placed over the user’s face. In some embodiments, when in use, the treatment unit 2 extends to cover the surrounding areas of the eyes.
  • the treatment unit 2 may have a visor or spectacle/glasses shape to at least cover the eye and surrounding areas, although it is envisaged that the treatment unit 2 may extend across other areas of the face in use, such as in a full “face mask” type of configuration.
  • a full “face mask” configuration may, for example extend across the user’s face to cover most (if not all) of the forehead region 26, the sides of the face (infratemporal) 18, and most (if not all) of the jaw or cheek (mandibular/buccal) region 28.
  • Some embodiments may also cover a mouth or chin region. Some embodiments may not cover the user’s lips.
  • the treatment unit 2 comprises at least one arcuate or curved portion 3 to facilitate the treatment unit 2 extending across the eye region of the user between the temple regions on either side of the user’s head, in a similar manner to wraparound sunglasses.
  • the treatment unit 2 may comprise left and right side portions 4, 5 which when worn, correspond to the left and right sides of the user’s head, such as shown in Figs. 5 A and 5B.
  • the side portions 4, 5 may be positioned approximately around the temple regions in use.
  • the left side portion 4 is more clearly shown in Fig. IB, while the right side portion 5 is more clearly shown in Fig. 1A.
  • the left and right side portions 4, 5 may be symmetrical/mirror images of each other.
  • the treatment unit 2 comprises an upper section 6 and a lower section 7.
  • the upper section 6 may be disposed towards an eyebrow region of the user’s face.
  • the upper section 6 may alternatively extend onto or beyond the eyebrow region.
  • the lower section 7 may be disposed towards a cheek region of the user’s face.
  • the lower section 7 may alternatively extend onto or beyond the cheek region, such as shown in Figs. 5A and 5B and Figs. 7A and 7B.
  • the lower section 7 may curve or sweep upwards towards the upper section 6 to define a convex section 7A. In doing so, the convex section 7A allows the treatment unit 2 to extend towards the user’s ear in use, without impinging on the ear (such as shown in Figs. 5A and 5B).
  • FIGs. 5A and 5B are a simplified illustration of the positioning on the face and head of an embodiment of an apparatus that delivers photobiomodulation therapy to the eye(s) and surrounding areas.
  • This illustration demonstrates both front and side profile view showing the external view (Fig. 5A) of the apparatus and positioning and the areas of the face and head that are covered.
  • Fig. 5B represents a transparent view of both front and side profile view of the apparatus, demonstrating internal positioning and the areas of the face and head that are covered.
  • the treatment unit 2 may be removably attached to a frame 8, which allows the treatment unit 2 to be removed for repair, for example.
  • the frame 8 may extend partly or wholly around a perimeter of the treatment unit 2.
  • the frame 8 connects to the upper section 6.
  • the frame 8 may be similar in overall shape and function to the frame of a pair of spectacles/glasses, in which the frame provides a means to securely locate the treatment unit 2 in fixed relation to the user’s face in use.
  • the frame 8 may also come in various sizes, be adjustable or deformable, or comprise modular components to allow users to adjust or customize the shape and size of the frame 8 to better suit the size and shape of their face and thereby improve user comfort.
  • the frame 8 may comprise an interior or inner portion 9 of the treatment unit 2.
  • the interior portion 9 is configured to be facing the user’s face when the apparatus 1 is in use.
  • a photobiomodulation light source 15 is also disposed on the interior portion 9 so that the user’s face is exposed to the light emitted from the light source 15 when the apparatus 1 is in use. The operation of the apparatus 1 and the light source 15 will be discussed in more detail later herein.
  • the frame 8 and/or the treatment unit 2 are configured to fold or be collapsed into a more compact form, which may assist with storage and/or protection of the photobiomodulation light source 15 disposed on the interior portion 9.
  • the treatment unit 2 can be collapsed, so that the left side portions 4 and the right side portion 5 can be brought together.
  • the upper section 6 and the lower section 7 may be collapsed and brought together.
  • Such a collapsible arrangement may be facilitated by a hinge or hinges (to allow folding in half, for example), or by the treatment unit 2 being made of separable sub portions which are secured by a removable clip or latch mechanism, for example.
  • the frame 8 may comprise padding 81 on the interior or inner portion 9.
  • the padding 81 may bulge or extend outwardly from the interior portion 9 so that when the apparatus 1 is in use, the inner portion 9 (and the photobiomodulation light source 15) does not contact the user’s face.
  • the padding 81 does not bulge out from the interior portion 9, and is instead a consistent layer of padding 81 across the interior portion 9.
  • the thickness and location of the padding 81 may be adjusted or varied in order to maintain a fixed distance between the interior portion 9 (and the photobiomodulation light source 15) and the user’s face.
  • the padding 81 may also provide a cushioned surface to improve user comfort when the apparatus 1 is in use.
  • the padding 81 may be deformable so as to be mouldable to suit the shape of the user’s face.
  • the padding 81 may comprise a resilient foam, a memory foam, or a plastic bumper.
  • the padding 81 may comprise a textured or tacky surface so that when the padding 81 is in contact with the user’s face, the textured or tacky surface allows the padding 81 to lightly grip the skin so as to help hold the apparatus 1 in a fixed position on the user’s face.
  • the frame 8 may comprise supports or securing means 11.
  • the securing means 11 extends outwardly from the side portions 4, 5 so that in use, the securing means 11 provides a means to hold the apparatus 1 in position on the user’s face.
  • the securing means 11 may cooperate with the textured or tacky surface of the padding 81 to help hold the apparatus 1 in a fixed position on the user’s face. This may make it easier for the light source 15 to provide secure and consistent coverage of the desired areas of the user’s face during a photobiomodulation therapy session.
  • the securing means 11 comprises arms which rest on the user’s ears akin to the arms of spectacles/glasses.
  • the arms may have a curved shape which allows them to at least partially wrap around the user’s ear to provide improved stability and security.
  • the securing means 11 comprises a band or strap which wraps around the user’s head, akin to goggles.
  • the securing means 11 may be elastic, resiliently deformable, and/or comprise an adjustment mechanism so as to be adjustable in length and shape to cater to different head diameters and shapes.
  • the securing means 11 may be removable for cleaning or replacement.
  • the securing means 11 may be foldable, collapsible, or removable to allow the apparatus 1 to have a more compact or collapsed form when not in use.
  • the apparatus 1 may further comprise a power button 12.
  • the apparatus 1 may further comprise a control panel 13.
  • the apparatus 1 may further comprise a charging port 14.
  • the apparatus 1 may further comprise a photobiomodulation light source 15.
  • the apparatus 1 may further comprise a power source such as a battery, and/or a controller.
  • the charging port 14 provides a connection point for a charging cable to connect the apparatus 1 to an external power supply (such as mains electricity) to charge the power source.
  • the power source may be a rechargeable battery. In some embodiments, the power source is able to be charged wirelessly, such as by inductive charging.
  • the power button 12 may be a switch or other similar type of control interface which controls the output of the photobiomodulation light source 15.
  • the power button 12 is a simple power button such as an on/off switch.
  • the power button 12 may additionally have functions beyond “on” and “off’.
  • the power button 12 is a button, dial or slider which adjusts the output across a plurality of output levels.
  • the power button 12 may be adjustable between “on”, “low power”, “medium power”, “high power”, and “off’ settings/modes.
  • the apparatus 1 comprises an autotimer for therapy settings.
  • the apparatus 1 may comprise a programmable component that may be programmed or utilised by the user to customise therapy settings.
  • the apparatus 1 is configured to communicate wirelessly with other devices such as a smartphone, for example. Wireless communication may be achieved by Bluetooth, NFC, or over WiFi.
  • the apparatus 1 may communicate with other devices such as a smartphone, for example to facilitate such customisation of therapy settings via an app on the smartphone.
  • the control panel 13 may display operational data of the apparatus 1.
  • the control panel 13 may indicate the output level of the photobiomodulation light source 15, the charge level of the battery/power source, or whether the apparatus 1 is “on” or “off’.
  • the control panel 13 may indicate other useful information such as the duration of use; for example, a timer displaying the duration of the current photobiomodulation therapy session, and/or the amount of time remaining in the current photobiomodulation therapy session.
  • the control panel 13 may be an LCD or LED display, for example, and may comprise a capacitive/touch screen.
  • the apparatus 1 may comprise a speaker which is configured to communicate information about the apparatus 1, and/or to communicate details of the current photobiomodulation therapy session.
  • the speaker may emit a specific sound, series of sounds, or pre-recorded voice messages to signify particular events such as the charge/power status of the battery or the amount of time remaining in the session.
  • the power button 12, control panel 13, charging port 14, light source 15, and/or power source are connected to the controller.
  • the controller regulates the amount of light emitted from the light source 15 in order to allow the user to control the delivery of the photobiomodulation therapy.
  • the controller in response to a setting or mode of the power button 12, the controller regulates the amount of electrical power supplied from the power source to the light source 15.
  • the controller may also control or communicate with the timer to control the duration of the light emitted from the light source 15, and thereby the duration of the treatment.
  • the controller may indicate the operational status, such as the setting/mode and the battery life, on the control panel 13.
  • the controller may also select the type of light emitted from the light source 15.
  • the light source 15 may be configured to emit specific wavelengths of light.
  • the controller may communicate with memory or a data storage unit which contains instructions for specific pre-set therapy programs.
  • Each therapy program may cause light to be emitted from the light source 15 at different durations, wavelengths, and/or intensities.
  • the memory may also be able to store customised programs which the user can upload, for example via a smartphone app.
  • the memory may also be updated to receive software updates from the manufacturer.
  • the power button 12, control panel 13, and/or charging port 14 may be positioned on the apparatus 1 to be easily accessed by the user.
  • the power button 12 and/or the control panel 13 may be disposed on an exterior portion 10 of the treatment unit 2 to allow the status of the apparatus 1 to be easily seen by the user or by a third party (such as a person administering the photobiomodulation therapy to the user).
  • the control panel 13 and/or power button 12 features may be situated on the right and / or left side of the apparatus 1 as shown in Figs 1A and IB; however, this is illustrative and in no way limits the potential location or functionality of these components on the apparatus and merely serves as an example in this embodiment for explanatory purposes. This may be particularly useful when the apparatus 1 is in a compact or collapsed configuration, wherein the internal portion is obscured to protect the light source.
  • the treatment unit 2 further comprises the exterior or outer portion 10 which defines an exterior or outer surface.
  • the exterior portion 10 comprises a firm or rigid outer casing or shell 2A.
  • the outer casing 10 may be rigid so that it holds its shape and provides some protection of the light source 15 disposed on a reverse interior portion of the treatment unit 2.
  • Fig. 2B shows the reverse interior portion 9 of the treatment unit 2, which is oppositely disposed to the exterior portion 10.
  • the interior portion 9 defines an interior or inner surface, such as shown in Fig. 2B. At least part of the interior surface may be generally concave to facilitate a wraparound configuration of the treatment unit 2.
  • the interior portion 9 may comprise a rigid inner casing or shell. This may facilitate mounting and or protection of the light source 15.
  • the light source 15 comprises an array of light generating sources such as light emitting diodes (LEDs), organic light emitting diodes (OLED), lasers, or other suitable light sources that are adapted to emit light within a particular wavelength range correlating with the treatment of one or more specific skin-related and/or eye related conditions.
  • LEDs light emitting diodes
  • OLED organic light emitting diodes
  • lasers or other suitable light sources that are adapted to emit light within a particular wavelength range correlating with the treatment of one or more specific skin-related and/or eye related conditions.
  • the photobiomodulation is achieved using light emitting diodes as the source 15 of red to near infrared light.
  • LED technology generates negligible heat, is clinically proven to be safe, and has achieved non- significant risk status for human trials by the U.S. Food and Drug Administration.
  • the apparatus 1 utilizes a noncoherent light source 15 capable of irradiating the user’s face, on and around the eyes.
  • the light source 15 may comprise an array of light sources 15 which may be distributed across the inner portion 9 to provide the desired light coverage to the areas of the user’s face indicated in Fig. 5A and 5B.
  • the distribution of the array of light sources 15 may be uniform or irregular.
  • the light source 15 may comprise an array of several LEDs which are concentrated (that is, more LEDs per unit area) in particular sections of the inner portion 9 which correspond to specific regions of the user’s face when the apparatus 1 is in use.
  • the LEDs are arranged in a grid.
  • the light emitted by the light source 15 may vary in intensity and wavelength depending on the type of photobiomodulation therapy desired.
  • the light emitted by the light source 15 has a wavelength between 630-1000 nm.
  • the light emitted by the light source 15 may have a power intensity/target irradiance between 0.5 - 50 mW/cm2 for a time of 1 - 30 minutes (equivalent to an energy density of 0.5 - 25 J/cm2), according to Hamblin et al. “Biphasic Dose Response in Low Level Light Therapy” 2009. Exposure to light emitted by the light source 15 at these wavelengths and/or intensities may lead to improvement in dry eye conditions.
  • Such photobiomodulation treatment may lead to an improvement in the appearance of skin. Lor example, this may lead to an observable improvement in healing, reduced inflammation, redness, alleviating symptoms of dry eye symptoms and reducing the appearance of skin aging of the eyelid and areas surrounding the eye.
  • the improved tissue function may also result in increased serum melatonin levels resulting in improved sleep, more desirable tear production, and increased intradermal collagen resulting in improved skin health and appearance.
  • Peak wavelengths of 670nm and 830nm, with bandwidths of 25-30nm have been used in numerous experimental and clinical studies.
  • 670nm LED irradiation was administered at a power intensity between 25-50 mW/cm2 between 1-3 minutes to produce an energy density of 4 J/cm2.
  • This reduction in oxidative stress allows the cells of these tissues to function more optimally, resulting in, for example, increased collagen production, increased blood and lymphatic flow, and improved tissue function. This may result in advantages including but not limited to promoting healing, reducing inflammation, redness, alleviating symptoms of dry eye and reducing the appearance of skin aging surrounding the eye.
  • Fig. 2C is a section view of the apparatus 1 as viewed along the line marked as such in Fig. 2B and looking at the inside of the right-hand side of the apparatus 1.
  • the interior portion 9 and the exterior portion 10 are spaced apart, and in doing so provides a structure that defines a cavity 10A therebetween.
  • the interior portion 9 and the exterior portion 10 may be spaced apart by the frame 8, such that the frame 8 is sandwiched by the interior portion 9 and the exterior portion 10.
  • the cavity 10A is sufficiently spacious to house the required circuitry to service the light source 15, the power source, the charging port 14, the control panel 13 and the power button 12.
  • the circuitry may include at least one flexible circuit board to which the LEDs 15 are connected.
  • the interior portion 9 and/or the exterior portion 10 may be attached to the frame 8 by screws to allow disassembly for repair, for example to provide access to the controller and battery /power source.
  • Figs. 4A and 4B respectively show top and bottom views of the apparatus 1.
  • the frame 8 has a curved shape to generally correspond to the shape of the user’ s head, and thereby provide a more secure and comfortable fit.
  • the frame 8 is symmetrical about a reference centreline 40.
  • the frame 8 extends away from centreline 40, before curving around and back towards the centreline 40 near the temple region of the user’s head.
  • the arms 11 may also extend towards the centreline 40 at the ear region of the user’s head, and wrap slightly around the rear portion of the user’s head to provide a secure fit.
  • Figs. 4A and 4B show example placement of the padding 81 and how it bulges from the inner portion 9 to space the apparatus 1 from the user’s face.
  • the padding 81 may be placed in between the LEDs 15 so as to avoid blocking the emission of light.
  • the padding 81 may cover the entirety of the inner layer 16.
  • the padding 81 is transparent or translucent to allow the light emitted from the LEDs 15 to pass through and irradiate the skin.
  • the padding 81 comprises light diffusing material to allow the light emitted from the LEDs 15 to pass through the light diffusing material and irradiate the skin. The light diffusing material may reduce the perceived brightness and/or glare of the LEDs 15, as may be perceived by the user while wearing the apparatus 1.
  • Fig. 4C is an exploded view of the apparatus 1, according to some embodiments.
  • the apparatus 1 comprises a treatment unit 2 made from multiple layers.
  • the treatment unit 2 may comprise the shell 2 A, and a second layer 15A.
  • the shell 2A comprises the frame 8, which may define raised edges or lips 2B and a recess 2C for receiving the second layer 15A.
  • the lips 2B may define the perimeter of the recess 2C, and be raised so that the inner portion 9 sits approximately flush with the lips 2B when the second layer 15A is received in the recess 2C.
  • the second layer 15A may be a body which houses the circuitry, componentry such as controller, battery, and power source, and the light source(s) 15 as previously identified.
  • the frame 8 may additionally define a hole or socket 14A which aligns with the charging port 14 when the second layer 15A is received in the recess 2C.
  • the apparatus 1 further comprises a third layer 16.
  • the third layer 16 sits in closest proximity to the face.
  • the third layer 16 may be made from a soft, comfortable material and comprise the padding 81.
  • the third layer 16 may have a light diffusing quality, and may provide protection for the light sources 15.
  • the light diffusing quality of the third layer 16 may reduce the perceived brightness and/or glare of the light sources 15, as may be perceived by the user while wearing the apparatus 1.
  • the third layer 16 may be moulded to match the shape of the apparatus 1 and/or be moulded to the shape of the human face/head.
  • the multiple layers may be disassembled to allow for easier maintenance and repair. For example, the third layer 16 may require cleaning or replacement after prolonged or repeated exposure to skin oils and sweat. Similarly, if the light source 15 requires replacement, the second layer 15A can be replaced without requiring replacement of the entirety of the apparatus 1.
  • the user may self-administer photobiomodulation treatment by placing it on the head, similar to a pair of glasses (as exemplified by Fig. 5A and Fig. 5B), pressing the power button 12, choosing setting if required (via the control panel 13), initiating therapy and allowing the apparatus 1 to deliver the treatment which can last from any time from 1-30 minutes, depending on required dosing, programming of device and requirements of user.
  • the apparatus 1 will have an auto timer component and will automatically switch off when treatment time and programmed dose has completed.
  • the functionality of the apparatus 1 can include the ability to operate each wavelength of light at a time, both wavelengths at the same time, or each wavelength in succession.
  • the apparatus 1 can be connected to a smart phone or other device wirelessly and controlled via an application.
  • This application could be used to select a specific treatment plan or protocol based upon the user’s preference or professional advice, as well as record treatment data over a course of time.
  • This application could also monitor other device functionality, including battery levels and possibly update firmware if appropriate.
  • FIG. 6 is a simplified illustration of the areas of the face and head that the apparatus will deliver photobiomodulation light therapy to. More specifically including, but not limited to the following areas of the face/head; across the entire orbital (22), infraorbital (21) and supraorbital (24) regions, including the eyebrow and glabella (23) areas, covering below the tear trough across the nasal region (25) and the midsection of the face, including the zygomatic region (20) spanning to the infratemporal (18), pre auricular (27), parotid (17) and temporal (19) regions on both sides.
  • Figs. 7A, 7B, and 7C show a further embodiment of the apparatus 1, denoted as apparatus 70.
  • the apparatus 70 comprises a treatment unit 72 (corresponding to the treatment unit 2) which covers the user’s eyes when the apparatus 1 is placed over the user’s face.
  • the treatment unit 2 and the treatment unit 72 cover the cheek area.
  • the treatment unit 2 and the treatment unit 72 may cover the same amount or regions of the cheek area.
  • the treatment unit 72 extends lower over the cheek area than treatment unit 2.
  • the treatment unit 72 may cover a larger amount or region of the cheek area than the treatment unit 2.
  • the treatment unit 72 covers the cheek and the nose area. In some embodiments, the treatment unit 72 extends over the cheek area but does not extend over the nose area, such as shown in Figs. 7A and 7B. In such embodiments, the treatment unit 72 comprises two halves 72A and 72B, which in use, may correspond to the left and right sides of the user’ s face in a similar way to the left and right side portions 4, 5.
  • the halves 72 A and 72B of the treatment unit 72 may be connected by a bridge portion 72C.
  • the light source 15 may extend across the bridge portion 72C between the halves 72 A and 72B to provide photobiomodulation therapy to the area of skin beneath (which may generally correspond to the bridge of the nose and the area between the eyebrows). In some embodiments, the light source 15 does not extend between the halves 72 A and 72B, and so the bridge portion 72C does not provide photobiomodulation therapy.
  • the apparatus 70 may further comprise a hinge or releasable means at the bridge portion 72C so that the two halves 72A and 72B can be separated for storage as previously disclosed.
  • the lower section 7 of the treatment unit 72 extends rearward so as to define a concave section 73.
  • the concave section 73 allows the treatment unit 72 to extend and provide coverage of the user’s face below the ears, around the sides of the user’s jaw bone.
  • the concave section 73 extends to cover the mandibular and/or buccal regions of the user’s face, as shown on Fig. 6 (item 28).
  • Fig. 7C shows the apparatus 70 when not in use.
  • the treatment unit 72 comprises the at least one arcuate or curved portion 3 to facilitate the treatment unit 2 extending across the eye region of the user between the temple regions on either side of the user’s head, in a similar manner to wraparound sunglasses.
  • the treatment unit 72 further comprises the upper section 6 and the lower section 7.
  • the treatment unit 72 may be removably attached to a frame 78.
  • the frame 78 is functionally equivalent to the frame 8 and comprises similar features such as the interior portion 9 and the exterior portion 10.
  • the frame 78 may be collapsible or foldable in the same ways previously discussed herein in relation to the frame 8.
  • Fig. 8A shows a front view of the apparatus 70 in the same way as Fig. 2A shows the front of the apparatus 1.
  • Fig. 8B shows a rear or inside view of the apparatus 70 in the same way as Fig. 8B shows the rear/inside of the apparatus 1.
  • Fig. 9A shows a right side view of the apparatus 70 in the same way as Fig.
  • FIG. 3 A shows the right side of the apparatus 1.
  • Fig. 9B shows a left side view of the apparatus 70 in the same way as Fig. 8B shows the left side of the apparatus 1.
  • the difference in shape and coverage provided by the concave section 73 compared to the convex section 7A is apparent when comparing Figs. 9A and 9B with Figs. 3A and 3B.
  • Fig. 10A shows a top view of the apparatus 70 in the same way as Fig. 4A shows the top of the apparatus 1.
  • Fig. 10B shows a bottom or underside view of the apparatus 70 in the same way as Fig. 4B shows the bottom or underside of the apparatus 1.
  • Fig. IOC is an exploded view of the apparatus 70, similar to Fig 4C which shows the exploded view of the apparatus 1.
  • the apparatus 70 comprises a treatment unit 72 made from multiple layers.
  • the treatment unit 72 may comprise the shell 2A, and a second layer 15A.
  • the shell 2A comprises the frame 78, which similar to the frame 8 may define raised edges or lips 2B and a recess 2C for receiving the second layer 15A.
  • the lips 2B may define the perimeter of the recess 2C, and be raised so that the inner portion 9 sites approximately flush with the lips 2B when the second layer 15A is received in the recess 2C.
  • the second layer 15A may be a body which houses the circuitry, componentry such as controller, battery, and power source, and the light source(s) 15 as previously identified.
  • the frame 78 may additionally define a hole or socket 14A which aligns with the charging port 14 when the second layer 15A is received in the recess 2C.
  • the apparatus 70 further comprises the third layer 16.
  • the third layer 16 sits in closest proximity to the face.
  • the third layer 16 may be made from a soft, comfortable material and comprise the padding 81.
  • the third layer 16 may have a light diffusing quality, and may provide protection for the light sources 15.
  • the light diffusing quality of the third layer 16 may reduce the perceived brightness and/or glare of the light sources 15, as may be perceived by the user while wearing the apparatus 70.
  • the third layer 16 may be moulded to match the shape of the apparatus 70 and/or be moulded to the shape of the human face/head.
  • the multiple layers may be disassembled to allow for easier maintenance and repair. For example, the third layer 16 may require cleaning or replacement after prolonged or repeated exposure to skin oils and sweat. Similarly, if the light source 15 requires replacement, the second layer 15A can be replaced without requiring replacement of the entirety of the apparatus 70.
  • the apparatus 1, 70 can be used to improve the functionality of the tissue of and around the eyes.
  • An example of a method for improving the functionality of the tissue of and around the eyes may comprise applying light with a predetermined set of photobiomodulating parameters to the eyes and surrounding areas tissues using the apparatus 1, 70.
  • the light emitted from the apparatus 1, 70 may have wavelengths in the range of 600 nm +/- lOnm to 900 nm +/- 10 nm. Applying the light in this way may result in reduction of oxidative stress of the tissues exposed to this light, thereby improving cellular respiration and resulting in improved tissue function.
  • Certain wavelengths of light at certain intensities will, for example, aid tissue regeneration, resolve inflammation, relieve pain and boost the immune system. Furthermore, it is agreed that the mechanism of action is photochemical rather than heat related. Observed biological and physiological effects include changes in cell membrane permeability, and up- regulation and down-regulation of adenosine triphosphate and nitric oxide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

L'invention concerne un appareil pour l'administration d'une thérapie par photobiomodulation (PBM). L'appareil comprend une unité de traitement. L'unité de traitement définit une surface interne et une surface externe, l'unité de traitement étant configurée pour être portée par un utilisateur de telle sorte que la surface interne de l'unité de traitement fait face à une zone de l'œil de l'utilisateur. L'appareil comprend un réseau de sources de lumière qui est couplé à la surface interne de l'unité de traitement, le réseau étant configuré pour émettre des ondes lumineuses à partir de la surface interne de l'unité de traitement. L'appareil comprend un dispositif de commande connecté de manière fonctionnelle au réseau et configuré pour commander l'émission des ondes lumineuses. Chacune des sources de lumière dans le réseau est configurée pour émettre les ondes lumineuses vers l'extérieur à partir de la surface interne de l'unité de traitement pour fournir une stimulation photodynamique du tissu couverte par la surface interne.
PCT/AU2022/050750 2021-07-16 2022-07-15 Appareil et procédé de photobiomodulation Ceased WO2023283699A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2021902200 2021-07-16
AU2021902200A AU2021902200A0 (en) 2021-07-16 Photobiomodulation apparatus and method

Publications (1)

Publication Number Publication Date
WO2023283699A1 true WO2023283699A1 (fr) 2023-01-19

Family

ID=78207566

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2022/050750 Ceased WO2023283699A1 (fr) 2021-07-16 2022-07-15 Appareil et procédé de photobiomodulation

Country Status (2)

Country Link
AU (1) AU2021106215A4 (fr)
WO (1) WO2023283699A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202300008307A1 (it) * 2023-04-27 2024-10-27 Espansione Marketing S P A Dispositivo per il trattamento dei disturbi oculari

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12474035B2 (en) 2022-04-13 2025-11-18 Delta Electronics, Inc. Lighting device with regions of differing spectral ranges
US20250082955A1 (en) * 2023-09-07 2025-03-13 Paul Salsberg Photobiomodulation Light Therapy Device And System Thereof

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350275B1 (en) * 1997-06-09 2002-02-26 The Board Of Trustees Of The Leland Stanford Junior University Devices for treating circadian rhythm disorders using LED's
US20040044384A1 (en) * 2002-09-03 2004-03-04 Leber Leland C. Therapeutic method and apparatus
WO2008131343A1 (fr) * 2007-04-19 2008-10-30 Mergenet Medical, Inc. Contrôle temporel en photothérapie
WO2010076707A1 (fr) * 2008-12-30 2010-07-08 Koninklijke Philips Electronics, N.V. Système et procédé pour appliquer une photothérapie à un sujet
DE202011050692U1 (de) * 2010-07-16 2011-09-26 Toni Hoyer Vorrichtung zur Lichtsimulation von biologischem Gewebe, insbesondere für den Augenbereich
WO2011141842A1 (fr) * 2010-05-14 2011-11-17 Koninklijke Philips Electronics N.V. Système utilisant deux ou davantage de bandes de longueurs d'onde de rayonnement électromagnétique pour administrer une luminothérapie à un sujet
US20130066404A1 (en) * 2011-09-08 2013-03-14 Jay Tapper Light therapy platform system
US20160067087A1 (en) * 2014-09-09 2016-03-10 LumiThera, Inc. Wearable devices and methods for multi-wavelength photobiomodulation for ocular treatments
WO2016040534A1 (fr) * 2014-09-09 2016-03-17 LumiThera, Inc. Dispositifs, systèmes et procédés de photothérapie à plusieurs longueurs d'onde pour le traitement non invasif de tissu endommagé ou malade
US20170224951A1 (en) * 2016-02-08 2017-08-10 Cornelia Weber Phototherapy sleep mask
CN207202991U (zh) * 2017-03-09 2018-04-10 中国人民解放军陆军军医大学 一种穿戴式经目光刺激眼镜
KR20180134624A (ko) * 2017-06-09 2018-12-19 (주)셀리턴 다파장 광원부를 구비하는 안면 마스크
US20190126060A1 (en) * 2018-05-04 2019-05-02 ShenZhen Kaiyan Medical Equipment Co, LTD Eyewear phototherapy device for eye cosmetology
CN208911300U (zh) * 2018-04-16 2019-05-31 南方科技大学 一种光疗眼膜
US20200171267A1 (en) * 2017-05-17 2020-06-04 Matthew D. Millard Head worn device for treating neurodegenerative diseases

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350275B1 (en) * 1997-06-09 2002-02-26 The Board Of Trustees Of The Leland Stanford Junior University Devices for treating circadian rhythm disorders using LED's
US20040044384A1 (en) * 2002-09-03 2004-03-04 Leber Leland C. Therapeutic method and apparatus
WO2008131343A1 (fr) * 2007-04-19 2008-10-30 Mergenet Medical, Inc. Contrôle temporel en photothérapie
WO2010076707A1 (fr) * 2008-12-30 2010-07-08 Koninklijke Philips Electronics, N.V. Système et procédé pour appliquer une photothérapie à un sujet
WO2011141842A1 (fr) * 2010-05-14 2011-11-17 Koninklijke Philips Electronics N.V. Système utilisant deux ou davantage de bandes de longueurs d'onde de rayonnement électromagnétique pour administrer une luminothérapie à un sujet
DE202011050692U1 (de) * 2010-07-16 2011-09-26 Toni Hoyer Vorrichtung zur Lichtsimulation von biologischem Gewebe, insbesondere für den Augenbereich
US20130066404A1 (en) * 2011-09-08 2013-03-14 Jay Tapper Light therapy platform system
US20160067087A1 (en) * 2014-09-09 2016-03-10 LumiThera, Inc. Wearable devices and methods for multi-wavelength photobiomodulation for ocular treatments
WO2016040534A1 (fr) * 2014-09-09 2016-03-17 LumiThera, Inc. Dispositifs, systèmes et procédés de photothérapie à plusieurs longueurs d'onde pour le traitement non invasif de tissu endommagé ou malade
US20170224951A1 (en) * 2016-02-08 2017-08-10 Cornelia Weber Phototherapy sleep mask
CN207202991U (zh) * 2017-03-09 2018-04-10 中国人民解放军陆军军医大学 一种穿戴式经目光刺激眼镜
US20200171267A1 (en) * 2017-05-17 2020-06-04 Matthew D. Millard Head worn device for treating neurodegenerative diseases
KR20180134624A (ko) * 2017-06-09 2018-12-19 (주)셀리턴 다파장 광원부를 구비하는 안면 마스크
CN208911300U (zh) * 2018-04-16 2019-05-31 南方科技大学 一种光疗眼膜
US20190126060A1 (en) * 2018-05-04 2019-05-02 ShenZhen Kaiyan Medical Equipment Co, LTD Eyewear phototherapy device for eye cosmetology

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202300008307A1 (it) * 2023-04-27 2024-10-27 Espansione Marketing S P A Dispositivo per il trattamento dei disturbi oculari
WO2024224431A1 (fr) * 2023-04-27 2024-10-31 Espansione Marketing S.P.A. Dispositif pour le traitement de troubles oculaires

Also Published As

Publication number Publication date
AU2021106215A4 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
AU2021106215A4 (en) Photobiomodulation apparatus and method
KR102013247B1 (ko) 얼굴 및 눈 노화방지를 위한 전기자극장치
CA2556222C (fr) Traitement de troubles de la vision au moyen d'energie electrique, lumineuse et/ou sonore
JP6410369B2 (ja) 認知状態を修正又は誘発する経皮電気刺激装置
US20240066315A1 (en) Therapeutic devices and methods to improve body functions
US11123572B2 (en) Eyewear phototherapy device for eye cosmetology
CN115955992A (zh) 改善身体功能的治疗装置和方法
CN101822872A (zh) 一种眼近红外光治疗仪
CN110368600A (zh) 一种光波脉冲负离子眼保仪及其控制方法
US20250010097A1 (en) Devices and methods for stimulating tear secretion
US10512586B1 (en) System and method for vision rehabilitation therapy
CN104941062A (zh) 一种防治青少年视力低下可加热的针灸仪
CN201019908Y (zh) 眼科治疗仪
TWI544916B (zh) 眼罩式眼部穴位雷射刺激裝置
JPH09224996A (ja) 眼部マッサージ器
CN107007931A (zh) 基于三联运动的多功能明目仪
KR101607372B1 (ko) 안구 피로회복 및 시력회복 장치
CN207871276U (zh) 基于三联运动的多功能明目仪
CN216497051U (zh) 智能视力康复理疗装置
WO2025244662A1 (fr) Système et procédé de stimulation électrique comprenant un ensemble plateforme d'électrode oculaire mobile permettant de positionner et ajuster des électrodes oculaires pour le traitement d'une maladie visuelle
CN210228473U (zh) 一种砭石护眼罩
CN211301105U (zh) 艾灸眼架
JP2024541493A (ja) 人の眼及び脳における神経細胞を活性化するためのシステム
CN113952184A (zh) 智能视力康复理疗装置
CN111714783A (zh) 光的热效应在近视眼防控的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22840877

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22840877

Country of ref document: EP

Kind code of ref document: A1